- Home
- MTNB vs CLGN Comparison
MTNB vs CLGN Comparison
Compare MTNB & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTNB | CLGN |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 5.2M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MTNB | CLGN |
|---|---|---|
| Price | $0.23 | $0.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 5.7M | 54.9K |
| Earning Date | 05-14-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,750.00 | N/A |
| Revenue This Year | N/A | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $0.27 |
| 52 Week High | $2.24 | $3.18 |
Technical Indicators
Market Signals| Indicator | MTNB | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.89 | 48.86 |
| Support Level | $0.23 | $0.29 |
| Resistance Level | $0.65 | $0.44 |
| Average True Range (ATR) | 0.04 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 8.42 | 62.21 |
Price Performance
Historical ComparisonAbout MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.